Regeneron: Antibody cocktail helps prevent symptomatic COVID-19
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2 by 81% in a phase 3 clinical trial conducted with the National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals announced yesterday.
The Food and Drug Administration has authorized emergency use of the therapy for people at high risk of progressing to severe COVID-19 or hospitalization. The company plans to ask the agency to expand the EUA to include COVID-19 prevention.
Related News Articles
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…